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RESEARCH ARTICLE
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Abstract
Background
Breast milk contains anti-rotavirus IgA antibodies and other innate immune factors that in-
hibit rotavirus replication in vitro. These factors could diminish the immunogenicity of oral
rotavirus vaccines, particularly if breastfeeding occurs close to the time of vaccine
administration.
Methods
Between April 2011 and November 2012, we conducted an open label, randomized trial to
compare the immunogenicity of Rotarix (RV1) in infants whose breastfeeding was withheld
one hour before through one hour after vaccination with that in infants breastfed at the time
of vaccination. The trial was conducted in the peri-urban area of Ibrahim Hyderi in Karachi,
Pakistan. Both groups received three doses of RV1 at 6, 10 and 14 weeks of age. Serocon-
version (anti-rotavirus IgA antibodies20 U/mL in subjects seronegative at 6 weeks of age)
following three vaccine doses (6, 10 and 14 weeks) was determined at 18 weeks of age (pri-
mary objective) and seroconversion following two doses (6 and 10 weeks) was determined
at 14 weeks of age (secondary objective).
Results
Four hundred eligible infants were randomly assigned in a 1:1 ratio between the withholding
breastfeeding and immediate breastfeeding arms. Overall, 353 (88.3%) infants completed
the study according to protocol; 181 in the withholding breastfeeding group and 172 in the
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immediate breastfeeding group. After three RV1 doses, anti-rotavirus IgA antibody serocon-
version was 28.2% (95% CI: 22.1; 35.1) in the withholding arm and 37.8% (95% CI: 30.9;
45.2) in the immediate breastfeeding arm (difference: -9.6% [95% CI: -19.2; 0.2] p=0.07).
After two doses of RV1, seroconversion was 16.6% (95% CI: 11.9; 22.7) in the withholding
arm and 29.1% (95% CI: 22.8, 36.3) in the immediate breastfeeding arm (difference:
-12.5% [95% CI: -21.2,-3.8] p=0.005).
Conclusions
Withholding breastfeeding around the time of RV1 vaccine administration did not lead to in-
creased anti-rotavirus IgA seroconversion compared with that seen with a breastfeed at the
time of vaccination. On the contrary, IgA seroconversion in infants immediately breastfed
tended to be higher than in those withheld from a feeding. Our findings suggest that breast-
feeding should be continued adlib around the time of rotavirus vaccination and withholding
breastfeeding at that time is unlikely to improve the vaccine immunogenicity.
Trial Registration
ClinicalTrials.gov NCT01199874
Introduction
Rotavirus is the leading cause of moderate to severe diarrhea in infants globally, causing an esti-
mated 453,000 deaths in 2008 [1]. Two oral rotavirus vaccines, 2-dose Rotarix (GlaxoSmithK-
line Biologicals, Rixensart, Belgium) (RV1) and 3-dose RotaTeq (Merck and Co., Inc.,
Whitehouse Station, NJ, USA) (RV5) are in use in in many countries. While highly efficacious
(~85%) against severe rotavirus disease in industrialized countries, these vaccines show sub-
stantially lower immunogenicity and efficacy (~51%-66%) against severe rotavirus in lower in-
come countries where most deaths from rotavirus occur [2, 3]. Factors that could explain this
difference in vaccine performance are increasingly becoming the focus of attention, given the
potential for significant impact by even modestly improving the effectiveness of rotavirus vac-
cines in developing countries.
Breastfeeding has been postulated as one possible factor that might impair rotavirus vaccine
performance [4]. Breast milk contains both secretory anti-rotavirus IgA antibodies as well as
innate immune factors such as lactoferrin, lactoadherin, mucin and butyrophilin which are in-
hibitors of rotavirus replication [4]. In an in vitro study in which breast milk from Bangladeshi
mothers was mixed with an equal volume of live serotype 1 rotavirus Wa strain, about 30% and
60% of breast milk samples neutralized 99% and 90% of the virus, respectively [5]. Recent stud-
ies by Moon et al demonstrated that the titers of neutralizing activity (NA) against three rotavi-
rus vaccine strains, RV1, RV5 G1 and 116E were higher in the breast milk of mothers in India
compared with mothers in the United States [6, 7]. This regional variation in NA could con-
tribute to the difference in immunogenicity of RV vaccine in developed and developing coun-
tries if indeed infants are receiving vaccine at the time that breast milk is also present in
sufficient quantity to reduce the effective inoculum.
If the high levels of NA and other factors in breast milk reduce the immunogenicity of the
vaccine when breast milk is provided at the same time as RV vaccine, withholding breastfeed-
ing for some time before and after vaccine administration could increase vaccine
Breastfeeding and Rotavirus Vaccine Immunogenicity
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immunogenicity. While withholding a feed may be difficult to implement programmatically, it
is important to understand if breast milk is an important factor contributing to the reduced
performance of current live oral rotavirus vaccines in developing countries so that program-
matic methods and/or new vaccines may be designed to overcome the effect. We therefore con-
ducted a randomized trial in Pakistan (where virtually all mothers breastfeed their young
infants), to compare the immunogenicity of RV1 in infants whose breastfeeding was withheld
one hour before through one hour after vaccination with each RV1 dose withthat in infants
who were breastfed at the time of vaccination. We also evaluated the effect of rotavirus neutral-
izing activity in breast milk on the immunogenicity of RV1.
Methods
Participants
The study was conducted in the peri-urban area of Ibrahim Hyderi in Karachi, Pakistan, where
the Department of Pediatrics and Child Health of Aga Khan University has conducted demo-
graphic surveillance, including pregnancy and newborn surveillance, since 2008. It is a low-
income community of predominantly fishermen. Neonatal and under 5 year mortality in this
population were 40.7 and 78.7 per 1000 live births in 2012, respectively.
Study recruitment was done from 11 April 2011 to 25 Jun 2012. Parents were informed of
the study when their infants were four weeks of age, and if interested, written informed consent
was obtained and their children enrolled at six weeks of age. Only infants whose mothers in-
tended to breastfeed their babies for at least 18 weeks were included in the trial. Infants were
excluded if they had a birth weight less than 1500 grams, received rotavirus vaccine outside of
the study, had received any immunoglobulin or blood products since birth, were on immuno-
suppressive drugs, or had used any investigational drug or vaccine within 30 days of the first
dose of study vaccine. Final follow up of the last participant was completed on 24 Sep 2012.
The trial was approved by the institutional review boards of Aga Khan University, the United
States Centers for Disease Control and Prevention, and the Western Institutional Review
Board (Olympia, WA, USA). The study was conducted in accordance with the principles of the
Declaration of Helsinki and in compliance with good clinical practice guidelines; Clinical-
Trials.gov registration number NCT01199874.
Randomization and masking
This randomized trial of 400 children included two intervention arms with treatment alloca-
tion of 1:1. Infants were randomized to one of two groups, according to computer-generated
randomization codes provided in sequentially numbered and assigned envelopes. The study
was partially blinded for logistical reasons; both participants and investigators were aware of
the group assignment but the laboratory scientists testing for rotavirus antibodies were not.
Procedures
Both study groups received three doses of the lyophilized formulation of RV1 at 6, 10 and 14
weeks of age. The regimen allowed for the assessment of the impact of breastfeeding in both
the conventional two dose schedule as well as the three dose regimen which was being studied
in a parallel trial [8]. Mothers randomized to the withholding breastfeeding arm were in-
structed to withhold breastfeeding for one hour before and after each RV1 dose at the study
clinic; mothers were allowed to breastfeed the infant in the clinic, if they desired, before the
monitored withholding period began. At the end of the withholding period (one hour after
RV1 receipt), mothers often left the clinic before resuming feeding so the exact duration of
Breastfeeding and Rotavirus Vaccine Immunogenicity
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withholding beyond the second hour was not consistently available. In the immediate breast-
feeding group, mothers were asked to breastfeed their baby for at least 20 minutes at the study
clinic, and the child was administered RV1 as soon as possible after the completion of breast-
feeding (maximum, 10 minutes after). The vaccination visits for the two arms occurred on dif-
ferent days of the week to ensure the appropriate feeding for each infant. The timing and
minimum duration of the withholding time or breastfeeding and the timing of the RV1 dose
were monitored closely and the success and timing of each step was documented by a study
nurse. At each vaccine visit, breast milk samples were expressed by both groups of mothers be-
fore the dose was administered. RV1 was provided along with trivalent oral poliovirus vaccine
(tOPV) and pentavalent vaccine (diphtheria, tetanus, whole cell pertussis, hepatitis B andHae-
mophilus influenzae type b), unless either had been administered earlier at another facility.
Vaccinations were postponed if the child was suffering from fever38.0°C, had vomited dur-
ing each of the last three feedings or met WHO criteria for some or severe dehydration [9]. The
study schedule is summarized in Table 1.
Laboratory Assays
Anti-rotavirus IgA antibody was measured in serum collected at age 6 weeks (pre-vaccination),
14 weeks and 18 weeks in all infants. The concentration of anti-rotavirus IgA antibody in
serum was measured using an enzyme-linked immunosorbent assay (ELISA) previously de-
scribed and expressed as Units per mL (U/mL)[10]. Neutralizing antibodies, presumed to be
maternally derived (MDNA), were measured in the infants' serum collected at 6 weeks using a
neutralization assay against rotavirus strain 89–12, the precursor to the RV1 vaccine strain, fol-
lowing methods previously described and expressed as the titer of the serum which represents
60% neutralization of the virus [11].
Anti-rotavirus IgA was measured in breast milk samples collected at 6, 10 and 14 weeks
using an ELISA previously described and expressed as titers [6]. Rotavirus neutralizing activity
in breast milk (BMNA) was assessed in the sample collected at 10 weeks using a neutralization
assay against the vaccine strain (RV1), following methods previously described [6]. Neutraliz-
ing titer in breast milk was determined as the reciprocal of the highest dilution that showed
greater than 70% reduction in the absorbance value compared with that in the virus-only con-
trol. The IgA and neutralizing assays used for the serum specimens were different from those
used for the breastmilk specimens and hence titers cannot be directly compared.
Safety Assessment
All infants were observed for at least 30 minutes after vaccine administration and parents were
asked to seek care at the study clinic for any illnesses in participants during the study period.
All serious adverse events (SAEs) were reported to an independent safety monitor who charac-
terized possible relationship to study product.
Table 1. Vaccination and Specimen Collection Schedule for both Group 1 and Group 2.
Study Visit 1 (V1) Study Visit 2 (V2) Study Visit 3 (V3) Study Visit 4 (V4)
6 weeks 10 weeks 14 weeks 18 weeks
Age: 42 to 55 days Age: 25 to 41 days post V1 Age: 25 to 41 days post V2 Age: 25 to 41 days post V3
Blood draw Blood draw Blood draw
Breast milk sample Breast milk sample Breast milk sample
RV1 and EPI vaccinations RV1 and EPI vaccinations RV1 and EPI vaccinations
Safety evaluation Safety evaluation Safety evaluation
doi:10.1371/journal.pone.0127622.t001
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Outcomes
Seroconversion was defined as a serum concentration of anti-rotavirus IgA antibodies20 U/mL
in subjects who were seronegative (IgA<20 U/mL) at 6 weeks of age. Seroconversion following
three doses (6, 10 and 14 weeks) was determined at 18 weeks of age (primary objective) and se-
roconversion following two doses (6 and 10 weeks) was determined at 14 weeks of age (second-
ary objective).
Analyses were conducted on the per protocol cohort, which included infants meeting all in-
clusion and no exclusion criteria, who were anti-rotavirus IgA seronegative at 6 weeks, received
RV1 vaccines and blood draws according to schedule with no significant deviations, and re-
mained in the study through 18 weeks. The breastfeeding requirements for the per-protocol co-
hort included documentation that the observed pre-dose and post-dose withholding period
were each 60 minutes (withholding arm) or infants received RV1 within 10 minutes after an
observed successful breastfeed (immediate arm).
We expected that any independent role of BMNA in impacting seroconversion would be
most likely revealed by examining infants in the immediate feeding arm with low MDNA. We
chose a priori to measure BMNA in the 10-week breast milk sample for two reasons: 1) it is ex-
pected that the 10-week vaccine dose is less impacted by serumMDNA compared to the
6-week dose, thus the independent effect of BMNA would be better assessed with a sample col-
lected at a later dose, and 2) many infants would likely seroconvert after two vaccine doses and
hence evaluating BMNA around the third dose (14 weeks) would be less informative. There-
fore, infants in the immediate arm were divided into a high and low BMNA groups using the
median BMNA titer as the cut point, and similarly were also divided into high and low MDNA
groups using their median MDNA titer, and comparisons were made of serconversion follow-
ing RV1 administration in these sub-groups.
Statistical analysis
Serum rotavirus IgA seroconversion between the withholding and the immediate breastfeeding
arms were compared using the Fisher Exact test and 95% confidence intervals (CI) of the differ-
ences in seroconversion were calculated based on the Newcombe-Wilson method without con-
tinuity correction. Serum anti-rotavirus IgA geometric mean titers (GMT) were compared
across arms using a t- test for all infants as well as seroconverted infants; t-test was used to
compare the log-transformed titers and 95% CIs were constructed based on the t-test. GMTs
and 95% CI of GMTs were results of anti log-transformation of the log-transformed results. A
value of 10 U/mL was assigned to infants with a IgA level of<20 U/mL for statistical purposes.
To assess the overall relationship between MDNA in the 6 week serum sample and BMNA in
the 10 week sample, Spearman’s rank correlation was used for both arms combined.
Enrollment of 200 infants in each arm was estimated to provide 85% power to detect a
17.5% difference in seroconversion after three vaccine doses between the withholding arm and
the immediate breastfeeding arm, using a 2-sided Chi Square test (alpha 0.05), assuming a 45%
seroconversion in the immediate breastfeeding arm, 5% IgA seropositivity at 6 weeks, and a
20% drop out during the study. Data analyses were performed using SAS and Stata software.
Role of Funding Source
The study was supported by PATH through funding from the Global Alliance for Vaccines
and Immunization (GAVI). The corresponding author had full access to all the data and had
final responsibility for the decision to submit for publication.
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Results
Study Population
Study arms were similar with respect to age, gender, length, weight, and family/household
characteristics at the time of enrollment (Table 2). Of the 400 children enrolled, nine (2.2%)
Table 2. Baseline Characteristics and Age at Study Visit.
Withholding
breastfeeding Arm
(N = 200)
Immediate breastfeeding
Arm (N = 200)
N % or Mean (SD) n % or Mean (SD)
Male; % 89 45.0 108 54.0
Age in Weeks; mean (SD) 200 6.3 (0.5) 200 6.3 (0.5)
Length (cm); mean (SD) 200 53.5 (2.5) 200 53.7 (2.5)
Weight (g) at 6 weeks; mean (SD) 200 3939.1 (619.2) 200 4047.5 (594.7)
FOC (cm) at 6 weeks; mean (SD) 200 36.7 (1.6) 200 36.9 (2.0)
Age of Mother (years); mean (SD) 200 26.1 (4.5) 200 25.6 (5.1)
Mother Years of Schooling; mean (SD) 200 4.7 (4.5) 200 4.7 (4.5)
Father Years of Schooling; mean (SD) 200 5.5 (4.7) 200 5.6 (4.7)
Type of milk
Exclusive breastfed;% 153 76.5 158 79.0
Breast milk plus formula;% 46 23.0 42 21.0
Exclusive formula milk;% 1 0.5 - -
Main source of water
Piped in/out dwelling; % 106 53.0 115 57.5
Tube/deep tube well; % 1 0.5 1 0.5
Surface well; % - - 1 0.5
Surface water; % 33 16.5 26 13.0
Bottled/ﬁltered; % 50 25.0 49 24.5
Other; % 10 5.0 8 4.0
Main material of roof
Jute/bamboo/mud; % 4 2.0 4 2.0
Tin; % 10 5.0 6 3.0
Cement/concrete; % 186 93.0 189 94.5
Other; % - - 1 0.5
Main type of toilet
Septic tank/modern toilet; % 14 7.0 17 8.5
Pit latrine, water sealed; % 25 12.5 28 14.0
Pit latrine, not water sealed; % 161 80.5 155 77.5
Place of delivery
Home; % 75 37.5 70 35.0
Hospital/Clinic; % 125 62.5 130 65.0
Age of visit in weeks†; mean (SD)
Visit 2 181 10.4 (0.5) 172 10.4 (0.6)
Visit 3 181 14.6 (0.6) 172 14.6 (0.6)
Visit 4 181 18.7 (0.7) 172 18.7 (0.7)
†per-protocol population
doi:10.1371/journal.pone.0127622.t002
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were anti-rotavirus IgA positive in serum collected at age 6 weeks, and were therefore dropped.
Overall, 353 (88.3%) infants completed the study according to protocol (Fig 1).
In the per-protocol population, the mean age of infants at each study visit was similar across
intervention arms. tOPV vaccine was given concomitantly with each dose of RV1 in 95% of
participants in each arm; the remaining children had documentation of receiving tOPV doses
from an outside facility. Birth dose of tOPV had been received, per parental report, by 87% of
infants (similar in both arms), and additional monovalent OPV or bivalent OPV doses were re-
ceived by study infants during vaccine campaigns that occurred during the trial period. The
Fig 1. Study Assignment and Follow-Up of Participants.
doi:10.1371/journal.pone.0127622.g001
Breastfeeding and Rotavirus Vaccine Immunogenicity
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GMT of MDNA against rotavirus, measured in infants’ serum at age 6 weeks, was similar in
the withholding and immediate breastfeeding arms; 116.2 (95%CI: 99.1; 136.2) and 96.5 (95%
CI: 81.4;114.3), respectively.
Immune Response to RV1
After three RV1 doses administered at 6, 10, and 14 weeks, anti-rotavirus IgA antibody sero-
conversion was 28.2% (95% CI: 22.1; 35.1) in the withholding arm and 37.8% (95% CI: 30.9;
45.2) in the immediate arm (difference: -9.6% [95% CI: -19.2; 0.2] p = 0.07) (Table 3). Anti-
rotavirus IgA GMT at 18 weeks was 20.4 U/mL and 23.1 U/mL in the withholding and imme-
diate breastfeeding arm, respectively; the GMT of the seropositive infants were not significantly
different between arms (Table 4).
After two doses of RV1 at 6 and 10 weeks, anti-rotavirus IgA antibody seroconversion was
16.6% (95% CI: 11.9; 22.7) in the withholding arm and 29.1% (95% CI: 22.8, 36.3) in the imme-
diate breastfeeding arm (difference: -12.5% [95% CI: -21.2, -3.8] p = 0.005) (Table 3). Anti-ro-
tavirus IgA GMT post-vaccination after the two dose regimen was 16.4 U/mL in the
withholding arm (seroconverters and non-seroconverters included) and 19.8 U/mL in the im-
mediate breastfeeding arm (p = 0.139) (Table 4). At age 14 weeks, the GMT of infants who
Table 3. Percent Anti-Rotavirus IgA Seroconversion.
Sample Withholding
breastfeeding
Arm
Withholding
breastfeeding
Arm
Withholding
breastfeeding
Arm
Immediate
breastfeeding
Arm
Immediate
breastfeeding
Arm
Immediate
breastfeeding
Arm
(N = 181) (N = 181) (N = 181) (N = 172) (N = 172) (N = 172) Difference in
seroconversion
P
value
n % 95% CI N % 95% CI
6 week 0 0 0 0
14
week
30 16.6 (11.9; 22.7) 50 29.1 (22.8; 36.3) -12.5 (-21.2; -3.8) 0.005
18
week
51 28.2 (22.1; 35.1) 65 37.8 (30.9; 45.2) -9.6 (-19.2, 0.2) 0.07
*Post hoc comparison for seroconversion at 14 or 18 weeks of age: Withholding (n = 56, 30.9%); Immediate (n = 76, 44.2%); difference -13.2 (95% CI
-23.3; -3.2), p = 0.011
doi:10.1371/journal.pone.0127622.t003
Table 4. Anti-Rotavirus IgA Geometric Mean Titers (GMT).
Withholding Breastfeeding arm Immediate Breastfeeding arm
Sample n GMT (U/mL) 95% CI N GMT (U/mL) 95% CI P value
All subjects
6 week 181 10.0 (10.0; 10.0) 172 10.0 (10.0; 10.0)
14 week 181 16.4 (13.7; 19.5) 172 19.8 (16.5; 23.7) 0.139
18 week 181 20.4 (16.9; 24.6) 172 23.1 (19.1; 28.0) 0.362
Seroconverted subjects†
14 week ‡ 30 194.4 (126.2; 299.3) 50 104.4 (77.3; 140.9) 0.016
18 week § 51 125.4 (91.0; 172.9) 65 91.8 (69.1; 121.8) 0.147
†Subjects with anti-rotavirus IgA 20 U/mL at 14 or 18 weeks, respectively.
‡Includes only anti-rotavirus IgA seropositive subjects at 14 weeks
§Includes only anti-rotavirus IgA seropositive subjects at 18 weeks
doi:10.1371/journal.pone.0127622.t004
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were seropositive was significantly higher in the withholding arm compared to the immediate
arm (194.4 U/mL (95%CI: 126.2; 299.3) vs.104.4 U/mL (95%CI: 77.3; 140.9) p = 0.016).
In the withholding arm, 17.2% (26/151) of those who were seronegative at 14 weeks were sero-
positive at 18 weeks following the third dose, and 16.7% (5/30) of those seropositive at 14 weeks
were seronegative at 18 weeks (S1 Fig). In the immediate breastfeeding arm, 21.3% (26/122) of
those seronegative at 14 weeks became seropositive following a third dose and 22.0% (11/50) of
those seropositive became seronegative. Within both arms, the IgA GMT of those infants who
had seroconverted by 14 weeks after 2 doses was similar to their GMT at 18 weeks, suggesting
that the 3rd dose did not substantially boost the immune response in these infants (S1 Fig).
Evaluation of Breast Milk Rotavirus Neutralizing Activity
Anti-rotavirus IgA titers in breast milk samples were similar between the two arms at each
time point 6, 10 and 14 weeks (data not shown). The GMT of BMNA in the 10-week breast
milk samples was similar in the withholding and immediate breastfeeding arms; 6.6 (95% CI:
5.2; 8.3) and 5.4 (95% CI: 4.3; 6.9), respectively.
The BMNA titer at 10 weeks was highly positively correlated with the serumMDNA titer at
6 weeks (p<0.001). When examining infants in the immediate feeding arm with low MDNA
(<median titer of 109.4 in serum at 6 weeks of age), those with low BMNA (<median of 4 in
breast milk collected 10 weeks post-partum) had higher seroconversion after two RV1 doses
(44.4%) compared with those with higher BMNA (20.0%) (p-value 0.019) (Table 5), suggesting
some inhibition by breast milk. At age 18 weeks after three RV1 doses, however, seroconver-
sion was similar (38.9% vs. 38.0%) (p-value 1.0) (Table 5).
Safety assessment
Four SAEs were observed in each of the two study arms including two deaths in the withhold-
ing arm and one death in the immediate breastfeeding arm. An independent safety monitor
found none of the SAEs related to the study vaccine.
Discussion
In this study, withholding breastfeeding for one hour before and after the time of RV1 vaccine
administration did not lead to increased anti-rotavirus IgA seroconversion compared with that
seen with a breastfeed at the time of vaccination. In fact, to our surprise, IgA seroconversion
after two RV1 doses at 6 and 10 weeks (the WHO recommended vaccination schedule) was sig-
nificantly greater in immediately breastfed infants compared with those in whom breast milk
was withheld, and this trend persisted after three RV1 doses although it did not remain statisti-
cally significant. Although serum rotavirus IgA is just one component of the immunological re-
sponse to the vaccine and not necessarily a mechanistic correlate of protection, our findings
suggest that substantially improved clinical protection is not likely with the strategy of with-
holding breastfeeding around the administration of RV1.
While immediate breastfeeding did not have a negative impact on IgA immune responses in
our overall study population receiving two or three vaccine doses at young ages, some nuances
need to be carefully considered. As has been demonstrated in vitro [5], our results from infants
in the immediate feeding arm with low MDNA suggest that ingesting breast milk with higher
BMNA at the same time as vaccine may reduce the subsequent immune response in some in-
fants. Additionally, the GMT in seropositive infants at 14 weeks was higher in the withholding
arm compared with the immediate arm. These latter two observations indicate that breast milk
interference may occur in a subset of young infants, such as those with low MDNA and ingest-
ing milk with high BMNA at the time of a particular dose.
Breastfeeding and Rotavirus Vaccine Immunogenicity
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It is unclear why IgA seroconversion in infants immediately breastfed tended to be higher
than in those who were withheld from a feeding, opposite to our hypothesis. Buffering of gastric
acid at the time of vaccine administration has been recognized as an important requirement for
oral rotavirus vaccine ‘take’ [12]; RV1 is buffered with calcium carbonate. Our findings may
suggest that additional buffering (as with a feed) may be worthwhile to investigate for some pop-
ulations. This could be examined by evaluating a similar population but among whom formula
feeding is more common, so as to isolate the effect of the possible additional buffering action of
a concomitant feed. It is also possible, however, that this is a chance finding, possibly from dif-
ferences in wild-type rotavirus exposure between the arms despite randomization. In a group of
infants enrolled concomitantly as subjects in this study from a nearby area who did not receive
rotavirus vaccine, background anti-rotavirus IgA seroconversion by age 18 weeks was 13.3% [8].
Our conclusion on lack of benefit of withholding a breastfeed is similar to that from a recent
randomized trial from South Africa, which found that infants who were withheld a breastfeed
for one hour before and after RV1 administration did not have improved immunogenicity (de-
fined as4-fold rise in serum anti-rotavirus IgA) after one or two doses of RV1 at 6 and 15
weeks, respectively, compared with infants in which unrestricted breastfeeding was encouraged;
unlike our study, a documented immediate feed was not required and initially seropositive in-
fants were included in the analysis [13]. Lack of overall benefit of withholding could be partially
explained if a study population had very low levels of BMNA. Compared to BMNA from other
populations reported from the same laboratory conducting our testing (but with a smaller num-
ber of samples for each population, and variable maternal and infant ages), the median titer of
BMNA against RV1 in the 10-week samples from Pakistani mothers in our evaluation (titer 4)
appears to be intermediate between that of US or Vietnamese (titer 2), Korean (titer 8) or South
African mothers (titer between 8–16), and lower than Indian mothers (titer between 32–64); the
infants in these studies had median age of about 3 months (range 4–29 weeks)[6, 7].
In conclusion, withholding breast feeding around the time of rotavirus vaccination does not
appear to improve rotavirus vaccine immunogenicity in our study population. Alternative ave-
nues to further augment immunogenicity and ultimately effectiveness of these vaccines in de-
veloping settings should be pursued.
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